drugset / Trial / NCT07799220
A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
Phase 2
Not yet recruiting
45 enrolled
Memorial Sloan Kettering Cancer Center
BeOne Medicines · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The researchers are doing this study to find out whether the combination of zanubrutinib, obinutuzumab, and sonrotoclax (BOSon) is an effective treatment approach for people with mantle cell lymphoma (MCL).
Timeline
- Start
- 2026-09
- Primary completion
- 2028-09
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | — | Intravenous |
| Subject | Sonrotoclax | Other / unclassified | — | — |
| Subject | Zanubrutinib | Small molecule | — | Oral |